Literature DB >> 34559275

Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR.

Meltem Alkan Melikoglu1, Sebnem Ataman2, Hatice Bodur3, Hasan Fatih Cay4, Erhan Capkin5, Ozgur Akgul6, Remzi Cevik7, Feride Gogus8, Ayhan Kamanli9, Fatma Gul Yurdakul3, Gulcan Gurer10, Ilker Yagci11, Aylin Rezvani12, Mehmet Tuncay Duruoz13, Ismihan Sunar14.   

Abstract

The rheumatoid arthritis impact of disease (RAID) score was developed as a patient-derived composite response index for the evaluation of the disease impact on cases with rheumatoid arthritis (RA). The aim of this study was to evaluate the psychometric properties and performance of RAID score in the real-life settings. Cases with RA from our multi-center, nationwide registry called Biologic and targeted Synthetic antirheumatic drugs Registry RA (BioStaR RA) were included in this cross-sectional observational study. Demographic data, disease duration, pain, patient's global assessment (PGA) and physician's global assessment (PhyGA) were recorded. DAS28-ESR, DAS28-CRP, the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI) were assessed as disease activity evaluations. The health assessment questionnaire-disability index (HAQ-DI) and RAID were completed by all the participants. The construct validity was tested by the analysis of correlations between RAID score and scores of PGA, disease activity indexes and HAQ-DI. We also evaluated the discriminatory ability of RAID to distinguish patients with different levels of disease activity and disability and the cut-off values were calculated by ROC analysis. 585 cases with RA were included in this investigation. The RAID score was significantly positively correlated with PGA, all disease activity indexes and HAQ-DI (p < 0.001). The discriminatory ability of RAID score in different disease activity and disability groups was also demonstrated (p < 0.001). To estimate DAS28-ESR (remission/low + moderate + high), RAID score cut-off points were 2.88 (sensitivity 73%, specificity 62%), 3.23 (sensitivity 75%, specificity 60%) and 3.79 (sensitivity 74%, specificity 58%), respectively. Our study indicated that RAID was a reliable tool in daily clinical practice by presenting its correlations with disease activity and disability assessments and by showing its discriminatory ability in these parameters in the real-life experiences.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Construct validity; Discriminatory ability; Rheumatoid arthritis; The rheumatoid arthritis impact of disease (RAID)

Mesh:

Substances:

Year:  2021        PMID: 34559275     DOI: 10.1007/s00296-021-04992-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

2.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

Authors:  Michael Drummond; Marco Barbieri; John Cook; Henry A Glick; Joanna Lis; Farzana Malik; Shelby D Reed; Frans Rutten; Mark Sculpher; Johan Severens
Journal:  Value Health       Date:  2009-01-12       Impact factor: 5.725

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.

Authors:  Eisuke Inoue; Hisashi Yamanaka; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

5.  Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis.

Authors:  Fausto Salaffi; Marco Di Carlo; Jelena Vojinovic; Angela Tincani; Alberto Sulli; Stefano Soldano; Laura Andreoli; Francesca Dall'Ara; Ruxandra Ionescu; Katarina Simić Pašalić; Ineta Balčune; Iván Ferraz-Amaro; Malgorzata Tlustochowicz; Irena Butrimienė; Egle Punceviciene; Natalia Toroptsova; Simeon Grazio; Jadranka Morović-Vergles; Pavol Masaryk; Kati Otsa; Miguel Bernardes; Vladimira Boyadzhieva; Maurizio Cutolo
Journal:  Joint Bone Spine       Date:  2017-05-24       Impact factor: 4.929

6.  Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative.

Authors:  L Gossec; S Paternotte; G J Aanerud; A Balanescu; D T Boumpas; L Carmona; M de Wit; B A C Dijkmans; M Dougados; M Englbrecht; F Gogus; T Heiberg; C Hernandez; J R Kirwan; E Martin Mola; M Matucci Cerinic; K Otsa; G Schett; M Scholte-Voshaar; T Sokka; G von Krause; G A Wells; T K Kvien
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

7.  Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative.

Authors:  L Gossec; M Dougados; N Rincheval; A Balanescu; D T Boumpas; S Canadelo; L Carmona; J-P Daurès; M de Wit; B A C Dijkmans; M Englbrecht; Z Gunendi; T Heiberg; J R Kirwan; E M Mola; M Matucci-Cerinic; K Otsa; G Schett; T Sokka; G A Wells; G J Aanerud; A Celano; A Dudkin; C Hernandez; K Koutsogianni; F N Akca; A-M Petre; P Richards; M Scholte-Voshaar; G Von Krause; T K Kvien
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

8.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

Authors:  A M van Gestel; M L Prevoo; M A van 't Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1996-01

9.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

Authors:  A M van Gestel; C J Haagsma; P L van Riel
Journal:  Arthritis Rheum       Date:  1998-10

10.  Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study.

Authors:  Karen Holten; Joseph Sexton; Tore K Kvien; Anna-Birgitte Aga; Espen A Haavardsholm
Journal:  RMD Open       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.